PRODUCT
SEARCH
NEWS
- ILDONG Pharmaceutical Publishes 2025 Sustainability Report 2025.06.05 Includes ESG Management Status and Achievements Across Environmental, Social, and Governance SectorsAiming to Become a S...
- ILDONG Pharmaceutical Successfully Hosts Launch Symposium for ‘Cuninta-Nintedanib’, a Treatment for Interstitial Lung Disease (ILD) 2025.04.28 Over 80 Respiratory Medicine Specialists from Across Korea Attend to Share the Latest Insights in ILDILDONG Pharmaceutic...
- iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis 2025.02.13 iLeadBMS, a spin-off biotech from Ildong Pharmaceutical Group, announced that it has received a notification from the US...
- ILDONG Pharmaceutical Participates in ‘CPhI Worldwide 2024' 2024.10.10 Ildong Pharmaceutical Participates in CPhI Worldwide 2024, Aiming to Expand Global Markets and Diversify Business Explor...
- ILDONG Pharmaceutical Publishes 2024 Sustainability Management Report 2024.07.03 Showcasing ESG Achievements and Future Corporate Vision Reaffirming Commitment to Becoming a Sustainable Global Healthc...
